Johnson & Johnson (NYSE:JNJ) Given Consensus Rating of “Buy” by Brokerages

Johnson & Johnson (NYSE:JNJ) has received an average rating of “Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $148.56.

JNJ has been the topic of a number of analyst reports. Raymond James lowered their price objective on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. BMO Capital Markets lifted their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a report on Thursday, July 18th. Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Tuesday, May 28th. They set a “buy” rating on the stock. Finally, Barclays began coverage on Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock.

JNJ traded up $0.07 during trading on Thursday, reaching $130.29. The company’s stock had a trading volume of 7,249,553 shares, compared to its average volume of 7,022,724. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The firm has a fifty day moving average of $136.91. The company has a market capitalization of $342.90 billion, a P/E ratio of 15.93, a price-to-earnings-growth ratio of 2.25 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the company earned $2.10 EPS. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

In other news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $139.68 per share, with a total value of $419,040.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.23% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of JNJ. Evolution Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after acquiring an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. raised its holdings in Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 80 shares during the last quarter. FNY Investment Advisers LLC raised its holdings in Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after acquiring an additional 428 shares during the last quarter. Finally, Thor Advisors LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at $69,000. Hedge funds and other institutional investors own 66.78% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What are the advantages of the Stochastic Momentum Index?

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.